Comparison
Ozempic vs Wegovy vs Zepbound
This comparison should keep product names, indications and official labels clear so readers do not treat every GLP-1 topic as interchangeable.
CravingWise verdict
For weight-management comparisons, start with Wegovy and Zepbound because their labels include chronic weight-management uses. Treat Ozempic as a diabetes medicine that may be discussed off-label for weight loss only when a clinician explains why.
- Ozempic
- Semaglutide; FDA-labeled for type 2 diabetes uses, not chronic weight management
- Wegovy
- Semaglutide; FDA-labeled for chronic weight management and related indications
- Zepbound
- Tirzepatide; FDA-labeled for chronic weight management and OSA context in adults with obesity
- Last checked
- July 5, 2026
Comparison standard
Keep the comparison focused on verifiable differences: medication path, advertised price, membership terms, product type, support model and final checkout questions.
- Normalize cost
- Name product type
- Link to provider reviews
Active ingredient and label are separate questions
Ozempic and Wegovy both contain semaglutide, but the label, dose schedule and approved-use language differ. Ozempic's FDA label is built around type 2 diabetes uses and related risk-reduction language. Wegovy's label is built around chronic weight management, cardiovascular risk-reduction language for selected adults and other current label details. Zepbound is different again because it contains tirzepatide, a GIP/GLP-1 receptor agonist, and has its own prescribing information.
- Same active ingredient does not mean same product label.
- Ask whether the provider is using a medication on-label or off-label.
- Use FDA labels, not social posts, as the source of truth for approved uses.
Weight-management comparison
If the question is chronic weight management, Wegovy and Zepbound are the cleaner starting points because their official labels include weight-management uses. Ozempic may still appear in provider conversations, but for weight loss that usually means off-label prescribing. Off-label use is a clinician decision, not a marketing shortcut, and it should come with clear explanation of risks, alternatives and monitoring.
- Do not assume Ozempic is FDA-approved for weight loss because it is a GLP-1 medicine.
- Compare Wegovy and Zepbound using their own labels and dose paths.
- Ask how side effects, missed doses and contraindications are handled.
Ozempic is not the same label as Wegovy even though both use semaglutide.
Safety and cost checks before choosing
All three products have prescribing information that clinicians use to screen for contraindications, warnings, drug interactions and adverse reactions. Cost comparisons also need precision: insurance may treat diabetes and obesity indications differently, and cash-pay pricing can differ by product, dose, pharmacy and savings program. The safest consumer workflow is to confirm the exact brand, active ingredient, indication and total out-of-pocket cost before paying a provider.
- Confirm brand name, active ingredient and dosage form.
- Check whether insurance approval depends on diagnosis or prior authorization.
- Review boxed warnings and contraindications with a licensed clinician.
Decision filter
Product names and labels matter
A comparison is useful only when it separates confirmed facts from terms that still depend on eligibility, insurance, dose or checkout.
- Cost
- Medication path
- Support model
- Open questions
Common questions
What is the fairest way to compare these options?
Use the same evidence set for each option: total recurring quote, medication path, support model, source quality and unresolved checkout questions.
Educational content only. Do not use this page as medical advice or as a substitute for a licensed clinician, pharmacist or insurer reviewing your situation.